Answers are grounded in this paper and cite their sources.
Ileal bile acid transporter (IBAT) inhibitors, such as odevixibat, are promising new therapeutic options for the treatment of pruritus and the reduction of serum bile acid levels as potential driver of liver injury progression in patients with cholestatic liver disease.1 Evidence is accumulating for the efficacy and safety of odevixibat in pediatric patients and in patients with compensated liver disease,2–8 but data are limited for adults in advanced icteric state. Herein, we present a case of stabilized liver function and reduction of severe pruritus during a 30 weeks treatment course with odevixibat followed by rapid deterioration with necessity of liver transplantation after cessation of treatment in an adult patient with advanced icteric cholestatic liver disease.
No takes yet. Share an insight, caveat, or question.
Herta et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: